USANA Health (USNA) AI Stock Analysis

• Market Cap: $375.49M
• Dividend Yield: N/A
• Average Volume (3M): 187.51K
• Price to Earnings (P/E): 23.1
• Beta (1Y): 1.03
• Revenue Growth: 5.88%
• EPS Growth: -68.62%
• Country: US
• Employees: 1,700
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): -0.15
• Shares Outstanding: 18,271,835
• 10 Day Avg. Volume: 275,735
• 30 Day Avg. Volume: 187,510
• PEG Ratio: -0.48
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 0.80
• P/FCF Ratio: 13.36
• Enterprise Value/Market Cap: 1.15
• Enterprise Value/Revenue: 0.62
• Enterprise Value/Gross Profit: 0.79
• Enterprise Value/Ebitda: 6.37
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $22.50 ▲(8.80% Upside)

USANA Health's overall stock score reflects a stable financial position with strong gross margins and low leverage. However, the company faces challenges with declining revenues and net profit margins. Technical indicators suggest bearish momentum, and valuation metrics indicate moderate pricing. The recent earnings call provided a mixed sentiment, with strategic initiatives offering potential upside. Addressing revenue declines and improving sales productivity are crucial for future performance.

USANA Health Business Overview & Revenue Model

Company Description

USANA Health Sciences, Inc. is a global nutritional company that develops and manufactures high-quality nutritional supplements, personal care products, and healthy lifestyle products. Established in 1992, USANA operates primarily in the health and wellness sector, focusing on products that support overall health, immunity, and performance. The company markets its products through a direct selling model, empowering independent distributors to sell USANA products directly to consumers, thereby creating a community-centered approach to health and wellness.

How the Company Makes Money

USANA generates revenue primarily through the sale of its nutritional supplements and personal care products. The company's revenue model is based on a direct selling approach, where independent distributors purchase products at wholesale prices and sell them at retail prices, keeping the difference as profit. This creates a dual revenue stream: the sale of products to consumers and the commissions paid to distributors based on their sales performance and the sales of their recruited team members. Additionally, USANA benefits from a strong brand reputation and customer loyalty, which contribute to repeat purchases. The company also invests in marketing strategies and partnerships that enhance its visibility and product reach, further supporting its revenue growth.

USANA Health Financial Statement Overview

Summary

USANA Health demonstrates strong gross profit margins and a solid balance sheet characterized by low leverage and strong equity. However, the company faces challenges with declining revenues, reduced net profit margins, and lower free cash flow growth. The overall financial position remains stable, but the company needs to address revenue and net income declines for improved financial performance.

Income Statement

USANA Health has experienced a declining revenue trend over the last few years, with a revenue decrease of approximately 7% from 2023 to 2024. The gross profit margin in 2024 was strong at around 81%, indicating efficient cost management. However, net profit margin decreased to about 4.92% in 2024 compared to 6.92% in 2023, reflecting pressure on net income. Despite this, the company maintains a solid EBIT margin at 7.76% in 2024. Overall, the company shows strong gross margins but faces challenges with declining revenues and net profitability.

Balance Sheet

USANA Health's balance sheet reflects a strong equity position with an equity ratio of approximately 71.1% in 2024, indicating financial stability and low leverage. The debt-to-equity ratio remains low at 0.04, demonstrating conservative financial management and limited reliance on debt. Return on equity decreased to 7.9% in 2024 from 12.8% in 2023, indicating reduced profitability on equity investments. Overall, the company's balance sheet is robust, supported by strong equity and low debt levels, although ROE has seen a decline.

Cash Flow

The cash flow analysis shows a modest decrease in free cash flow from 2023 to 2024 by about 9.3%. The operating cash flow to net income ratio is healthy, suggesting efficient cash generation relative to net income. However, the free cash flow to net income ratio has declined, reflecting less cash available after capital expenditures. Despite these challenges, USANA Health continues to generate positive operating cash flow. Overall, cash flows are positive, but there is a downward trend in free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2019	Dec 2018
Income Statement
Total Revenue	699.06M	854.50M	921.01M	998.60M	1.06B	1.19B
Gross Profit	547.61M	693.29M	744.32M	804.71M	873.40M	988.54M
EBITDA	67.48M	98.86M	123.11M	130.22M	146.19M	188.35M
Net Income	12.54M	42.03M	63.79M	69.35M	100.53M	126.22M
Balance Sheet
Total Assets	726.59M	748.19M	632.76M	596.55M	516.93M	554.46M
Cash, Cash Equivalents and Short-Term Investments	145.35M	181.77M	330.42M	288.42M	234.83M	277.87M
Total Debt	0.00	39.20M	13.21M	6.89M	8.32M	0.00
Total Liabilities	145.04M	161.86M	135.56M	162.08M	165.22M	163.32M
Stockholders Equity	528.07M	532.11M	497.20M	434.47M	351.71M	391.15M
Cash Flow
Free Cash Flow	14.71M	50.92M	56.15M	93.50M	110.16M	140.69M
Operating Cash Flow	25.74M	60.99M	70.64M	103.90M	126.73M	152.12M
Investing Cash Flow	-11.23M	-213.09M	-11.97M	-12.37M	47.49M	-69.00M
Financing Cash Flow	-54.06M	9.55M	-14.24M	-30.09M	-152.05M	-105.28M

USANA Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 20.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USNA, the sentiment is Negative. The current price of 20.68 is above the 20-day moving average (MA) of 20.48, below the 50-day MA of 25.60, and below the 200-day MA of 28.81, indicating a bearish trend. The MACD of -1.59 indicates Negative momentum. The RSI at 29.20 is Positive, neither overbought nor oversold. The STOCH value of 18.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for USNA.

USANA Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FTLF	72 Outperform	$176.08M	22.46	21.88%	―	3.91%	-1.39%
NATR	70 Outperform	$313.52M	22.08	9.15%	―	6.62%	-7.85%
LFVN	66 Neutral	$88.84M	9.27	33.31%	2.33%	16.77%	143.30%
HLF	65 Neutral	$950.46M	2.90	―	―	-0.78%	265.56%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
USNA	61 Neutral	$375.49M	23.09	3.20%	―	5.88%	-68.62%
LWAY	58 Neutral	$371.58M	35.31	14.46%	―	9.19%	-23.91%

USANA Health Corporate Events

USANA Health Sciences Reports Q3 2025 Results

USANA Health Sciences Inc., a company specializing in nutritional supplements, functional foods, and personal care products, operates in the direct selling industry with a significant presence in various international markets.

USANA Earnings Call: Mixed Sentiments and Strategic Moves

USANA Health Sciences Inc. recently held its earnings call, presenting a mix of positive developments and challenges. The sentiment expressed during the call was cautiously optimistic, with highlights including the rollout of an enhanced compensation plan and strong performances from Hiya and Rise Bar. However, the company also faced challenges such as softer sales, a decline in Hiya’s customer count, and a global cost reduction process.

USANA Health Reports Q3 2025 Sales Increase

USANA Health Sciences reported a 7% increase in net sales for the third quarter of 2025 compared to the same period in 2024, reaching $214 million. However, the company experienced a net loss of $6.5 million, attributed to investments in a new Brand Partner compensation plan and an increased effective tax rate. Despite these challenges, USANA remains optimistic about its long-term growth, supported by a successful Global Convention, new product launches, and a strategic focus on enhancing its Brand Partner network. The company also reported significant progress in its direct-to-consumer business, Hiya, which achieved 26% year-to-date sales growth and is expected to continue its upward trajectory.

The most recent analyst rating on (USNA) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on USANA Health stock, see the USNA Stock Forecast page.

USANA Health Reports Q3 2025 Preliminary Results

USANA Health Sciences announced preliminary third-quarter results for 2025, revealing net sales of approximately $214 million, up from $200 million in the same period last year. However, earnings from operations dropped significantly to $1.2 million compared to $15.6 million in 2024, attributed to challenges during the rollout of a new Brand Partner compensation plan and lower-than-expected sales from their direct-to-consumer business, Hiya. Despite these setbacks, USANA remains optimistic about long-term growth, emphasizing strategic initiatives to modernize operations and enhance Brand Partner productivity. The company also faced a substantial increase in the effective income tax rate, impacting profitability, and anticipates a lower earnings outlook for the full year.

The most recent analyst rating on (USNA) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on USANA Health stock, see the USNA Stock Forecast page.